Aiforia Technologies, a pioneer in AI-driven diagnostics in pathology, has announced a new partnership with PathPresenter. This collaboration aims to broaden the reach and adoption of Aiforia’s AI-powered image analysis solutions by utilizing PathPresenter's comprehensive pathology workflow platform.
Techcyte, a leader in AI-powered digital pathology, and Aiforia, a pioneering provider of deep-learning AI solutions for pathology, today announced a strategic partnership to accelerate the adoption of AI-driven workflows in anatomic pathology laboratories worldwide.
In this Thought Leaders episode, we explore the transformation of digital pathology and the critical role of AI-driven innovation. Joe discusses the challenges of AI adoption, the integration of IMS and AI, and how True Gigapixel technology is reshaping pathology workflows.
Techcyte, a leader in AI-powered digital pathology, Pramana, a provider of advanced whole slide imaging solutions, and Aiosyn, a developer of AI-driven pathology algorithms, today announced a collaboration to integrate AI-powered breast and kidney histopathology analysis directly into the digital pathology workflow.
While much of the industry conversation around AI in pathology has rightfully centered on image analysis applications—which is why we’ve created and continue to expand the industry’s leading precision medicine AI portfolio—our vision at Proscia goes further.
Techcyte, a leader in digital pathology and Aiosyn, a leading developer of AI-driven pathology algorithms, today announced a collaboration that brings Aisoyn’s AI algorithms to the Fusion digital pathology platform.
A pioneering study presented at the 22nd ENETS Conference in Krakow, Poland has highlighted the clinical potential of AI-assisted pathology in neuroendocrine neoplasms (NEN). Led by PD Dr. med. Daniel Kaemmerer, the study evaluated Mindpeak’s AI-powered pathology algorithms for SSTR2A and Ki-67 immunohistochemistry (IHC) scoring, demonstrating impressive clinical-grade performance.
The digital pathology (DP) revolution has been brewing for some time. For decades, the healthcare industry has been marching forward with technology investments, starting with adopting electronic health records (EHRs) and, more recently, digitizing many other aspects of health as a business, such as patient communications, virtual appointments, cloud-based technology and more. In fact, according to a 2024 McKinsey survey of healthcare leaders, the vast majority—90 percent, to be exact—named “digital transformation” as a top priority for their organizations.
Proscia®, a software company leading pathology’s transition to digital and AI, has secured $50M in funding, bringing its total raised to $130M. This investment follows Proscia’s record-breaking growth in 2024. Proscia now counts 16 of the top 20 pharmaceutical companies among its users and is on track for 22,000+ patients to be diagnosed on its Concentriq® software platform each day.
The collaboration aims to assess the transformative potential of AI in digital pathology, with a specific focus on accelerating primary breast cancer diagnosis. Breast cancer remains one of the leading causes of cancer-related deaths in women worldwide.
